We bring you exclusive sessions from our scientific workshops, featuring roundtable discussions with world-leading experts.
Each session focuses on a key topic aligned with the workshop program.
On-demand Sessions
Explore roundtable discussions from our scientific workshops
Approaches to managing FLT3-mutant AML
iwAL 202519 - 21 September, 2025
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
iwAL 202519 - 21 September, 2025
Novel approaches to upfront management of myelofibrosis
iwMPN 202527 - 29 June, 2025
Challenging and uncommon scenarios in MPNs
iwMPN 202527 - 29 June, 2025
Novel therapeutic approaches in MPNs: targeting CALR, immune modulation, & JAKi specificity
iwMPN 202527 - 29 June, 2025
Challenges of managing blast-phase MPNs: the role of transplant, impact of TP53 mutations & more
iwMPN 202527 - 28 June, 2025
Advances in the treatment of LR-MDS: luspatercept combinations, the use of imetelstat & more
iwMDS 202527 - 29 June, 2025
Advances made in MDS classification and risk stratification: ongoing work & future perspectives
iwMDS 202527 - 29 June, 2025
iwMDS wrap-up: translating research into practice to optimize patient care
iwMDS 202527 - 29 June, 2025
Novel targets in MDS: telomerase inhibition, the SELECT-MDS-1 trial, PK agonists, & more
iwMDS 202527 - 29 June, 2025
Evolving strategies in clinical trial design for MDS: defining response criteria
iwMDS 202527 - 29 June, 2025
CAR-T in ALL: dual targeting strategies, CAR-T in pediatric patients, managing ICANS, and more
iwCAR-T 202511 - 13 April, 2025
T-cell engagers and CARs in myeloid malignancies
iwCAR-T 202511 - 13 April, 2025
Translational insights into T-cell engagers and CAR T-cell therapy: targets, the microbiome, & more
iwCAR-T 202511 - 13 April, 2025
Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy
iwCAR-T 202511 - 13 April, 2025
T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions
iwCAR-T 202511 - 13 April, 2025
Integrating autoimmune diseases into cellular therapy centers
iwCAR-T 202511 - 13 April, 2025
CAR therapies in high-risk myeloma: current data, their role in high-risk subgroups, & the potential of alloCARs
iwHRMM 202423 - 25 October, 2024
Extramedullary disease in multiple myeloma: biology, the potential role of AI, and more
iwHRMM 202423 - 25 October, 2024
Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies
iwHRMM 202423 - 25 October, 2024
Defining high-risk multiple myeloma: recent advances in the field & future considerations
iwHRMM 202423 - 25 October, 2024
CTCs in HRMM: their value in diagnosis, prognosis, and guiding treatment decisions
iwHRMM 202423 - 25 October, 2024
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
iwAL 202413 - 15 September, 2024
Novel treatments & combinations in AML: mechanisms of resistance to venetoclax & approaching R/R disease
iwAL 202413 - 15 September, 2024
Novel targets, combinations & treatments in AML: use of OGM, TP53 treatment strategies & ADCs
iwAL 202413 - 15 September, 2024
Current data on menin inhibition in AML
iwAL 202413 - 15 September, 2024
Updates on established therapies in AML – Part 2
iwAL 202413 - 15 September, 2024
Updates on established therapies in AML – Part 1
iwAL 202413 - 15 September, 2024
Updates in HR-MDS therapies: IDH inhibitors, challenges with transplantation, and more
iwMDS 202428 - 30 June, 2024
Inflammation & immune interventions in MDS: targeting STAT, IRAK4 & more
iwMDS 202428 - 30 June, 2024
Updates in the diagnosis, classification & risk stratification of MDS
iwMDS 202428 - 30 June, 2024
CAR T-cells for autoimmune diseases
iwCAR-T 202419 - 21 April, 2024
The future of CAR-T therapy in AML
iwCAR-T 202419 - 21 April, 2024
Allo approaches in CAR-T
iwCAR-T 202419 - 21 April, 2024
An update on CAR-T in CLL
iwCAR-T 202419 - 21 April, 2024
Understanding mechanisms of resistance to targeted therapies in myeloma
iwMyeloma 202412 - 14 April, 2024
Early Interception In SMM & Novel Agents Being Explored
IBC Workshop 202414 - 16 March, 2024
Updates On The Biology And Treatment Of T-Cell Lymphoma
iwNHL 202329 September - 1 October, 2023
Clonal Hematopoiesis, Early Detection & Potential Therapeutics
iwAL 202325 - 27 August, 2023
CAR-T in AML: updates & challenges
iwCAR-T 202314 - 16 April, 2023
How can we improve efficiency of drug approval for MDS?
iwMDS 202224 - 26 June, 2022
Contact Us
If you would like more information, or are interested in supporting one of our on-demand sessions
